BMS Bags a Bargain
Sally Mardikian PhD
Abstract
BMS has agreed to buy Kosan Biosciences for US$190 M. For a company with a Phase III product in its pipeline, did Kosan get what it deserves?
Full Text: pdf html
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.